Skip to content

⌘K

Screener Chart SD50 Calendar News

Home Chart Calendar News

Clinuvel Pharmaceuticals Ltd. (CUVL) Stock | LOPJLB

Clinuvel Pharmaceuticals Ltd. (CUVL)

Healthcare · Medical - Pharmaceuticals · NASDAQ · AU

$4.94-1.79%Close

CUVL

$4.94-1.79%

Overview Financials Earnings Analyst & RatingsAnalyst News Holders & ETFsHolders Options

Snapshot

Price & returns

1 week: -5.7%-5.3% vs SPY
1 month: -14.7%-13.7% vs SPY

Valuation

Market cap: $249.1M

Short interest & options

Short % float: 0.0%
Days to cover: 1.1
Short change: -54.4%

Signal: Call, Regime, Alignment, Score, ATR trend, HiLo flip, Coil, Exhaustion, Topping · Technicals (EMA stack, slope, squeeze, stochastic, MACD-Z, DI+) · Price & returns: 3 months, Year to date, 1 year

Price & returns: 3 years, 5 years

Signal: Composite · Performance (Q-Score, Sharpe, Sortino, Calmar, CAGR, drawdown, alpha)

Signal evidence

Best Combo (today's action, held-out profit factor and family votes) · White Arrow (the call, its profit factor and closed trades) · Regime (today's regime and the regime model's profit factor) · Exhaustion (whether buyers or sellers are stretched today and the latest release)

Related

Lists

Quality dividend stocks

Prediction markets

Kalshi · Polymarket · … linked

Full prediction markets →

Loading markets…

Company

About

Clinuvel Pharmaceuticals Ltd. (CUVL). Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CU…

SEC filingsCIK 1290877

All filings
10-K
10-Q
8-K
Form 4

Profile

SectorHealthcare

IndustryMedical - Pharmaceuticals

ExchangeNASDAQ

CountryAU

CEOPhilippe Jacques Wolgen

IPOJul 13

Employees-

Shares outstanding50.4M

Float43.6M

Free float86.5%

Websiteclinuvel.com ↗

Key executives

Philippe Jacques WolgenCEO, MD & DirectorUSD 3.7M
Lachlan HayChief Operations OfficerUSD 385K
Dennis J. WrightChief Scientific OfficerUSD 257K
Peter VaughanChief Financial OfficerUSD 236K
Azza HamilaHead of Quality Assurance & Drug Safety
Emilie RodenburgerDirector of Global Clinical Affairs

Snapshot

Price & returns1 month -14.7%

1 week: -5.7%-5.3% vs SPY
1 month: -14.7%-13.7% vs SPY

Open the chart →

Valuationmarket cap $249.1M

Market cap: $249.1M

Open Financials →

Short interest & optionsshort 0.0% of float

Short % float: 0.0%
Days to cover: 1.1
Short change: -54.4%

Open Options →

Signal evidence

Related

Lists

Quality dividend stocks

Prediction markets

Kalshi · Polymarket · … linked

Full prediction markets →

Loading markets…

Company

About

Clinuvel Pharmaceuticals Ltd. (CUVL). Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CU…

SEC filingsCIK 1290877

All filings
10-K
10-Q
8-K
Form 4

Profile

SectorHealthcare

IndustryMedical - Pharmaceuticals

ExchangeNASDAQ

CountryAU

CEOPhilippe Jacques Wolgen

IPOJul 13

Employees-

Shares outstanding50.4M

Float43.6M

Free float86.5%

Websiteclinuvel.com ↗

Key executives

Philippe Jacques WolgenCEO, MD & DirectorUSD 3.7M
Lachlan HayChief Operations OfficerUSD 385K
Dennis J. WrightChief Scientific OfficerUSD 257K
Peter VaughanChief Financial OfficerUSD 236K

Company news

Loading headlines…

Market news & ticker search · RSS for CUVL

Congress trades

STOCK Act filings · … on file

Loading disclosures…

LOPJLB

Independent quant research on U.S. equities & ETFs. Not personalized advice.

Product

Screener Chart Compare SD50 News Calendar

Desk

Market Heatmap Market Hours FOMC Desk Treasury Rates Congress Trades Prediction Markets

Research

How It Works Methodology Track Record Docs Editorial Blog Changelog

Ledgers

Bull Spreads Cash-Secured Puts Covered Calls Long Puts Long Calls

Screeners

CEF Screener REIT Screener BDC Screener Preferred Screener Dividend Screener ETF Screener Crypto Screener S&P 500 Screener Best dividend stocks Undervalued stocks Best S&P 500 stocks

Company

Pricing About Contact

Agents

GitHub·Research Chat·MCP(Enterprise)·Developers

© 2026 LOPJLB Research. All rights reserved.

@lopjlb contact@lopjlb.com

RANGE

DATA 2026-10-23

LOPJLB.COM

OHLCOHLC, Essential layerEMAEMALEVELS, Essential layerSTOPStop, Essential layerFLIPFlip, Essential layer52W52-weekSIGNALS, Essential layerBUYBuy, Essential layerSELLSell, Essential layerEXHExhaustion, Essential layerEXH ZONEExhaustion zone, Essential layerCOILCoil

Oct 23, 2026O 5.00H 5.02L 4.93C 4.94-1.79%V 4.7K

Congress trades

STOCK Act filings · … on file

Full congress tracker →

Loading disclosures…